Zynex (ZYXI)
(Delayed Data from NSDQ)
$7.74 USD
-0.04 (-0.51%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $7.75 +0.01 (0.13%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.74 USD
-0.04 (-0.51%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $7.75 +0.01 (0.13%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth F Momentum C VGM
Zacks News
Zynex Stock Rises on FDA Clearance of Its New Pain Management Device
by Zacks Equity Research
ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.
Zynex Inc. (ZYXI) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Zynex (ZYXI) delivered earnings and revenue surprises of -50% and 3.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Zynex (ZYXI) Rating Upgrade to Buy
by Zacks Equity Research
Zynex (ZYXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Zynex (ZYXI) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Zynex (ZYXI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zynex (ZYXI) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Zynex (ZYXI) possesses solid growth attributes, which could help it handily outperform the market.
Are Investors Undervaluing Zynex (ZYXI) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Reasons Growth Investors Will Love Zynex (ZYXI)
by Zacks Equity Research
Zynex (ZYXI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -76.47% and 12.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q3 Earnings Match Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0% and 0.84%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 125% and 1.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 300% and 6.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 5.26% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Does Zynex Inc. (ZYXI) Have the Potential to Rally 65% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Zynex Inc. (ZYXI) points to a 65.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zynex Inc. (ZYXI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 8.33% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q1 Earnings Miss Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -40% and 0.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 21.05% and 1.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q3 Earnings Top Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 30.77% and -1.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Zynex Inc. (ZYXI) Could Rally 87%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Zynex Inc. (ZYXI) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zynex Inc. (ZYXI) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and -0.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
Zynex Inc. (ZYXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zynex Inc. (ZYXI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0.00% and 2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex (ZYXI) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zynex's (ZYXI) April orders down approximately 35% from the January and February average. This may have impacted its Q2 earnings.
Agios Gets Orphan Drug Tag for Mitapivat to Treat Thalassemia
by Zacks Equity Research
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.